Drug Trial Radar · NCT05279391
Combination of Inhaled DNase, Baricitinib and Tocilizumab in Severe COVID-19
Last checked: Nov 20, 2026Latest source record: Mar 15, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
150
Planned (sponsor's estimate)
Start
Oct 25, 2020
Primary completion
Nov 30, 2021
Study completion Dec 31, 2023
Sponsor
- Lead sponsor
- Democritus University of ThraceAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Mar 15, 2022
Design
- Study type
- Interventional
- Phase
- Not applicable
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 100 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
In patients with COVID-19, severe hypoxemic respiratory failure (SRF) leading to invasive mechanical ventilation (IMV), raises the mortality rate substantially. Thus, the management of patients with SRF to avoid intubation and intensive care admission is a challenging and crucial issue. This study describes, as rescue/compassionate treatment, a therapeutic protocol based on the multi-mechanistic nature of severe COVID-19, using the combination of inhaled DNase, Baricitinib and Tocilizumab on top of standard of care (SOC) consisting of heparin and dexamethasone. COVID-19 patients with SRF who were treated with SOC, SOC plus Anakinra (ANA), and SOC plus Tocilizumab (TOCI) will be studied as comparators. Primary endpoint will be the reduction of the in-hospital mortality rate, whereas secondary endpoints concern intubation rate, days of hospitalization and overall survival as derived from the last follow-up visit, either in-office or remote. This is a non-randomized, open-label, study, conducted in the First Department of Internal Medicine, University Hospital of Alexandroupolis, Greece.
Conditions
- COVID-19 Severe Respiratory Failure
Interventions
DexamethasoneDrug
Dexamethasone 6-8 mg once daily
Low molecular weight heparinDrug
Therapeutic doses of LMWH (e.g. Tinzaparin 175IU/kg)
Anakinra 100Mg/0.67Ml Inj SyringeDrug
IV administration of Anakinra 200 mg/twice daily for 3-6 days, then 100 mg/twice daily, for up to 10 days in total.
TocilizumabDrug
IV administration of Tocilizumab as a single dose of 8mg/kg
BaricitinibDrug
4 mg per os once daily, for up to 14 days (2 mg if GFR: 30 to \<60 ml/min/1.73 m2)
Dornase Alfa Inhalant ProductDrug
Inh. 2,500 U/twice daily, for up to 14 days.
Primary outcomes
What the sponsor says the trial is designed to measure.
- In-hospital mortality rateTime frame: Through study completion, an average of 1 year
Locations
1 site in 1 country. Site status is shown where the registry gives one.
University Hospital of Alexandroupolis
Alexandroupoli, Evros, Greece · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.